In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on Satsuma Pharmaceuticals (STSA), with a price target of $15.00. The company’s shares closed last Monday at $6.51, close to its 52-week low of $3.50.
According to TipRanks.com, Livnat is a 5-star analyst with an average return of 16.5% and a 57.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Verrica Pharmaceuticals.
Satsuma Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.33.
See today’s analyst top recommended stocks >>
Based on Satsuma Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.04 million. In comparison, last year the company had a GAAP net loss of $8.26 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
